Center for Molecular Cancer Research

RESEARCH LABORATORIES DEVELOPED IN VIPER

1. CENTRE FOR MOLECULAR CANCER RESEARCH (CMCR)

About: Centre for Molecular cancer research (CMCR) established as an interdisciplinary centre in the campus of Vishnu Institute of Pharmaceutical Education & Research (VIPER). The aim of the centre is to bridge the gap between Pharmaceutical and life science research and also to bring the multi-layered process of cancer drug discovery on to single platform. The focus of the new Centre will be to Screen and create compounds that are purpose-built to interrupt specific biochemical processes while avoiding harm to normal cellular functions. We at CMCR working on various disciplines like Medicinal chemistry, Computational chemistry and Cancer biology to understand the current global state of drug discovery.  The Centre for Molecular cancer research is playing a transformative role on this campus and well beyond our borders in the field of cancer research. The Centre has well sophisticated Cell culture facility and well-equipped Life science research facilities along with Computational & Medicinal chemistry laboratories.

Activities: 
1. Screening of novel synthesized molecules (SM’s) or Natural small molecules (NSM’s) or Plant extracts (PE) or fractionated plant extracts (FPE) against Morphological behaviour of different cancer cells.
2. Cell Viability/cytotoxicity assays by MTT, XTT and LDH.
3. Apoptotic evaluation of novel molecules using Fluorescence microscopic techniques.
4. Determination of gene expression by PCR array/Gene Expression analysis.
5. Protein expression analysis by SDS-PAGE and Western blot.

Measurable outcomes:

a) Publications: 
1. Nivetha R, Arvindh S, Baba AB, Gade DR, Gopal G, K C, Reddy KP, Reddy GB, Nagini S. Nimbolide, a Neem Limonoid, Inhibits Angiogenesis in Breast Cancer by Abrogating Aldose Reductase Mediated IGF-1/PI3K/Akt Signalling. Anticancer Agents Med Chem. 2022;22(14):2619-2636. DOI: 10.2174/1871520622666220204115151.

2. Sandhya Rani M, Srinivas L. Development of Solid Lipid Nanoparticles with Letrozole for Breast Cancer Treatment: in-vitro and in-vivo evaluation. (2022). Journal of Pharmaceutical Negative Results, 1159-1166. DOI: 10.47750/pnr.2022.13.S01.142

3. Ahsan M.J., Gautam K., Ali A., Ali A., Altamimi A.S.A., Salahuddin, Alossaimi M.A., Lakshmi S.V.V.N.S.M., Ahsan M.F. Synthesis, Anticancer Activity, and In Silico Studies of 5-(3-Bromophenyl)-N-aryl-4H-1,2,4-triazol-3-amine analogs. Molecules 2023 28, 6936. DOI: 10.3390/molecules28196936.

4. Ramesh Babu, V., Rangaswamy, S., Lakshmi, S., Musuluri, M., Mak, K. K., Syed, T. Abbaraju, V. D. N. K. (2024). Design, Synthesis, Anticancer Evaluation and Molecular Docking Studies of Amide Derivatives of Thienopyrimidine Isoxazoles. Organic Preparations and Procedures International, 56(5), 439–450. DOI: 10.1080/00304948.2024.2316449

5. Pavani Chowdary, Eswara Rao Puppala, Chandralekha Putta, Jagapathi Rao M, P. Vishnu, VVS Rajendra Prasad, Aravind Kumar R, Hyaluronic-Acid-Functionalized Tofacitinib Loaded Transethosomes for Targeted Drug Delivery in Rheumatoid Arthritis. ACS Applied Bio Materials 2025, 8, 2, 1594–1606. DOI: 10.1021/acsabm.4c01743.

6. Khalilullah H, Agarwal DK, Ahsan MJ, Jadav SS, Mohammed HA, Khan MA, Mohammed SAA, Khan R. Synthesis and Anti-Cancer Activity of New Pyrazolinyl-Indole Derivatives: Pharmacophoric Interactions and Docking Studies for Identifying New EGFR Inhibitors. Int J Mol Sci. 2022 Jun 11;23(12):6548. doi: 10.3390/ijms23126548.

b) Patents (Both granted and published)

1. Synthesis Of Nitric Oxide Donating 5,6-Di Phenyl 1,2,4-Triazinecarbamoyl and Sulphamoyl Aryl Nitrate Derivatives As cytotoxic Agents in Cancer Cells (Patent number: 483992)
3. Nitric Oxide Donating Quinazoline Fused Pyrazole Derivatives As Cytotoxic Agents in Cancer (Patent number: 418135)
4. Substituted Pyrazolopyrimidines as HER-2 and CDK4/6 Inhibitors and Uses Thereof (Application number: 202441002729)
5. Novel N10 - Substituted 2-Chloro Acridones, Molecular Docking, Lipophilicity and Cytotoxic Studies Against MCF–7 Cell Lines (Application number: 202341052682)
6. Pentaslanceolataextract and their in-vitrocolon cancer against HT-29 cell lines thereof(Application number: 202541018524)

2. A Method of Preparing Nitric Oxide Donating Quinazolinef used Pyrazole Derivatives as Cytotoxic Agents (Patent number: 418135)

c) Extramural grants received: 

1. “Development of an affordable test kit for early detection of colon cancer and GIT disorders” from MSME 
2. “Development of Nitric oxide-releasing quinoline derivatives as inhibitors of doxorubicin resistance in cancer cells” from AICTE
3. “Development and Characterization of letrozole loaded polymer based nanoparticulate formulations to induce programmed cellular death in breast cancers: in-vitro & amp; in-vivo evaluation studies” from ICMR
4. “Development of Nitric oxide releasing Quinoline derivatives as inhibitors of doxorubicin resistance in cancer cells” from DST